

malignant B cells but in all assessed cell types in the tumor microenvironment, including T cells, NK cells, and various types of myeloid cells. Surprisingly, however, expression of late replication genes was also detected in these healthy cell types, suggesting that viral replication following infection by T-VEC occurs not only in tumor cells. This may shed an unexpected light on the mechanism of action of T-VEC, which was previously thought to only replicate in malignant cells. The current single-cell transcriptome analysis may suggest that, besides immunogenic cell death of cancerous B cells by viral replication, cell death of non-malignant cell types induced by T-VEC administration may also contribute to the induction of an effector immune response and may amplify this immune response. To what extent T, NK, and myeloid cells, likewise malignant B cells, are initially cleared by T-VEC, or whether these cells are rather protected and take part in the effector response following T-VEC injection, however, remains to be elucidated.

Taken together, these observations illustrate the value of in-depth analysis of early sequential biopsies from T-VEC-injected lesions utilizing scRNA-seq, which complements the information on the long-term changes in the immune environment derived from later biopsies and revealed new insights into the mech-

anism of action of oncolytic virus therapy. Considering the early type I IFN response that was unleashed upon T-VEC, analysis of multiple (early and late) sequential post-treatment biopsies could—when feasible—also provide a more complete picture of the therapy-induced responses in other therapeutic settings, such as immune checkpoint blockade in cancer patients. As for T-VEC therapy, analysis of the early changes in the TME upon immune checkpoint treatment may help uncover unexpected or novel pathways that play crucial roles in the response to these agents.

ACKNOWLEDGMENTS

The authors thank W. Scheper for input and discussions.

DECLARATION OF INTERESTS

J.B.H. has received (institutional) financial compensation for advisory roles for Achilles Therapeutics, BioNTech, BMS, Gadeta, Immunocore, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, and Third Rock Ventures. J.B.H. received institutional research grants from Amgen, BioNTech, BMS, MSD, and Novartis. J.B.H. holds stock options for Neogene Therapeutics.

REFERENCES

Andtbacka, R.H.I., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K.A., Amatruda, T., Zager, J.S., Cranmer, L., Hsueh, E., et al. (2016).

Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTIM phase III clinical trial. *Ann. Surg. Oncol.* 23, 4169–4177.

Blank, C.U., Rozeman, E.A., Fanchi, L.F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018). Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat. Med.* 24, 1655–1661.

Clarke, J., Panwar, B., Madrigal, A., Singh, D., Gujar, R., Wood, O., Chee, S.J., Eschweiler, S., King, E.V., Awad, A.S., et al. (2019). Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. *J. Exp. Med.* 216, 2128–2149.

Grasso, C.S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D.Y., Shin, D.S., et al. (2020). Conserved interferon- γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. *Cancer Cell* 38, 500–515.e3.

Kaufman, H.L., Kohlhapp, F.J., and Zloza, A. (2016). Oncolytic viruses: a new class of immunotherapy drugs. *Nat. Rev. Drug Discov.* 15, 660.

Ramelyte, E., Tastanova, A., Balázs, Z., Ignatova, D., Turko, P., Menzel, U., Guenova, E., Beisel, C., Krauthammer, M., Levesque, M.P., and Dummer, R. (2021). Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. *Cancer Cell* 39, this issue, 394–406.

Sade-Feldman, M., Yizhak, K., Bjorgaard, S.L., Ray, J.P., de Boer, C.G., Jenkins, R.W., Lieb, D.J., Chen, J.H., Frederick, D.T., Barzily-Rokni, M., et al. (2018). Defining T cell states associated with response to checkpoint immunotherapy in melanoma. *Cell* 175, 998–1013.

Neutrophils create a fertile soil for metastasis

Kevin Kos¹ and Karin E. de Visser^{1,2,*}

¹Division of Tumor Biology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands

²Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands

*Correspondence: k.d.visser@nki.nl

<https://doi.org/10.1016/j.ccell.2021.01.009>

Neutrophils can facilitate the metastatic spread of cancer; however, how neutrophils are activated at metastatic sites remains poorly understood. In this issue, Xiao et al. demonstrate that the protease cathepsin C, secreted by breast cancer cells, triggers neutrophils to form neutrophil extracellular traps in the metastatic niche, thereby promoting lung metastasis.

Upon arrival in distant organs, disseminated cancer cells can only form metastases when they succeed in creating a permissive environment that fosters their

survival and outgrowth. While some members of the immune system can be harnessed to prevent metastatic spread, the role of others has proven to be context

dependent or even pro-metastatic. Among these immune cells are neutrophils. These granulocytic myeloid cells are well known for their key role in acute



inflammation and immune regulation and have recently gained much attention in the context of metastatic disease.

Neutrophil diversity, function, and fate are shaped by environmental cues, enabling their quick and effective adaptation to a great diversity of homeostatic and pathological conditions (Jaillon et al., 2020). During homeostasis, the phenotype and activity of these short-lived cells are mainly regulated by their tissue location, circadian oscillations, and cellular aging (Ballesteros et al., 2020). Disruption of homeostasis, for instance, during tumor development, can induce a drastic systemic mobilization of (partly immature) neutrophils from the bone marrow. Importantly, neutrophil accumulation in cancer patients has been associated with a worse prognosis (Gentles et al., 2015). In line with these clinical observations, preclinical studies have revealed that neutrophils can enhance metastasis formation through a variety of effector functions, including systemic suppression of T cells, preparation of the pre-metastatic niche, or promotion of cancer cell survival. In some preclinical settings, however, cancer-induced neutrophils inhibit metastasis, highlighting their functional plasticity (Jaillon et al., 2020). As such, it is of vital importance to understand the molecular mechanisms that drive the functional adaptations of neutrophils toward a metastasis-supporting phenotype, as this may uncover novel therapeutic opportunities. In this issue of *Cancer Cell*, Xiao et al. (2021) describe an intriguing pathway exploited by breast cancer cells to enhance their metastatic potential through the co-option of neutrophils in the metastatic lung niche.

An important cause of breast cancer-related mortality is lung metastasis, which has limited treatment options, in part due to poor understanding of critical interactions between disseminated cancer and host cells that foster their outgrowth. Xiao et al. (2021) set out to profile the secretome of breast cancer cell lines with varying degrees of lung metastatic potential to identify secreted factors that are potentially involved in creating a permissive metastatic niche. They discovered that cathepsin C (CTSC), a lysosomal cysteine protease, is consistently elevated in lung-tropic breast cancer cell lines. Cysteine cathepsin proteases are multifunctional proteolytic enzymes that

act in a wide range of biological processes and can exert their enzymatic activity both intracellularly (most notably in the lysosome) and extracellularly. Cathepsins are often dysregulated in cancer, and experimental evidence has specifically implicated CTSB, CTSK, CTSL, CTSS, and CTSZ in breast cancer metastasis (Olson and Joyce, 2015), whereas the role of CTSC has remained less clear, due to its context-dependent role in carcinogenesis (Ruffell et al., 2013).

By using a variety of intravenously injected and orthotopically transplanted breast cancer cell lines in mice, Xiao et al. (2021) showed that CTSC overexpression in cancer cells exacerbates lung metastasis, whereas knockdown of CTSC reduces the metastatic burden in lungs. While modulation of CTSC has no direct effect on primary tumor outgrowth, CTSC critically increases cancer cell proliferation early upon their colonization of the lungs, thus suggesting that CTSC improves the adaptation of disseminated cancer cells to their new micro-environment. The authors observed that tumor-derived CTSC induces the recruitment of neutrophils into the lungs through paracrine communication. Strikingly, antibody-mediated depletion of neutrophils completely abrogates the pro-metastatic effect of CTSC, uncovering a crucial interaction between CTSC-expressing cancer cells and neutrophils.

Also in breast cancer patients, an association between high intratumoral CTSC expression and poor survival was observed, and CTSC expression levels are particularly high in lung metastases versus primary tumors. These data are in line with previous clinical studies that have linked high CTSC expression to increased incidence of both brain and lung metastasis in breast cancer patients (Olson and Joyce, 2015). The current study from Xiao et al. (2021) provides insight into the pro-metastatic role of CTSC and warrants further research into whether the same axis is relevant for metastasis formation in the brain.

In an impressive set of mechanistic studies, Xiao and colleagues showed that cancer cell-derived CTSC enzymatically activates the serine protease PR3 expressed on the membrane of neutrophils (Figure 1). This process induces the activation of IL-1 β in lung neutrophils, which kick-starts an inflammatory

cascade involving the secretion of IL-6 and CCL3, resulting in the recruitment of additional neutrophils from the circulation. In parallel, IL-1 β activation also initiates intracellular production of reactive oxygen species (ROS) in neutrophils, which promotes the formation of neutrophil extracellular traps (NETs). NETs are extracellular web-like chromatin structures, made of DNA fibers, histones, and granule proteins, that are released from neutrophils primarily through an alternative cell death process called NETosis. These DNA traps play an important role in the defense against large pathogens by trapping microbes in place but have recently also been observed in the micro-environment of various human cancer types, including pancreatic, breast, lung, and liver cancer (Papayannopoulos 2018). Notably, the authors demonstrated that the *in vivo* destruction of NETs through treatment of mice with DNase I is sufficient to prevent the metastatic outgrowth of CTSC-expressing cancer cells in the lungs, highlighting a causal role for NETs in CTSC-enhanced metastasis formation. But how do these neutrophil-derived DNA traps enhance the metastatic potential of breast cancer cells?

Several mechanisms have been reported by which NETs can promote metastasis, including direct induction of cancer cell chemotaxis to the liver (Yang et al., 2020) and the awakening of dormant cancer cells in lungs (Albregues et al., 2018). Xiao and colleagues add a new mechanism to the list by demonstrating that NETs induce the degradation of the matricellular protein thrombospondin-1 (TSP-1), which has been shown to be important for tumor spheroid outgrowth *in vitro*. Combined, this study reveals an intriguing novel pathway by which tumoral CTSC expression dictates metastatic potential by exploiting neutrophils in the metastatic lung niche (Figure 1).

These novel findings raise the question of whether targeting the CTSC-PR3-IL1 β -NET axis represents a viable therapeutic strategy to prevent metastatic spread of CTSC-expressing breast cancer. Excitingly, the authors showed that a small molecule inhibitor of CTSC, brensocatib, suppresses experimental lung metastasis. Besides CTSC, IL-1 β might be an attractive actionable therapeutic target (Figure 1). Indeed, a recent clinical




Figure 1. Breast cancer cells gain metastatic potential through expression of CTSC

In the metastatic lung niche, cancer cell-derived CTSC activates PR3 on neutrophils, leading to a signaling cascade that promotes the recruitment of neutrophils from circulation and enhances NET formation via IL-1 β . In turn, cancer cells gain a proliferative advantage through the NET-mediated degradation of TSP-1, resulting in enhanced metastatic outgrowth. This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; <https://smart.servier.com>.

study has revealed that inhibition of IL-1 β in patients with atherosclerosis reduces lung cancer incidence, which associates with a reduction of tumor-promoting inflammation (Ridker et al., 2017). As of yet, it is unclear whether the efficacy of targeting the CTSC-PR3-IL1 β -NET pathway will be limited to preventing lung metastasis or whether it may also prevent metastases in other tissues. This may be dependent on the tissue-specific expression levels of TSP-1, thereby highlighting a clinically relevant direction for future research.

The clinical relevance of this work is supported by complementary findings in samples of several human breast cancer cohorts, showing that tumoral CTSC expression strongly correlates with neutrophil and NET markers, as well as with lung metastasis. Interestingly, by analyzing these cohorts, Xiao et al. (2021) found substantial interpatient heterogeneity of CTSC

expression and showed that CTSC is most highly expressed in triple-negative breast cancer. It is unclear how CTSC is regulated in different subtypes of breast cancer, and looking forward, an important next step would therefore be to identify the patient population that is most likely to benefit from therapeutic exploitation of these findings. Taken together, this study reveals a novel mechanism that confers breast cancer cells with enhanced metastatic potential through co-option of the immune system. Importantly, these insights open new avenues for the future design of therapeutic strategies aimed at blocking a cancer cell's ability to create a permissive metastatic niche.

ACKNOWLEDGMENTS

Research in the de Visser laboratory is funded by the Netherlands Organization for Scientific Research (NWO-VICI 91819616), the Dutch Can-

cer Society (KWF10083, KWF10623), and the Oncode Institute. K.K. is funded by the NWO Oncology Graduate School Amsterdam (OOA) Diamond Program.

DECLARATION OF INTERESTS

K.E.d.V. reports research funding from Roche and is consultant for Third Rock Ventures, outside the scope of this work.

REFERENCES

- Albregues, J., Shields, M.A., Ng, D., Park, C.G., Ambrico, A., Poindexter, M.E., Upadhyay, P., Uyeminami, D.L., Pommier, A., Küttner, V., et al. (2018). Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. *Science* 361, eaao4227.
- Ballesteros, I., Rubio-Ponce, A., Genua, M., Lusito, E., Kwok, I., Fernández-Calvo, G., Khojraty, T.E., van Grinsven, E., González-Hernández, S., Nicolás-Ávila, J.Á., et al. (2020). Co-option of neutrophil fates by tissue environments. *Cell* 183, 1282–1297.
- Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., Nair, V.S., Xu, Y., Khuong, A., Hoang, C.D., et al. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat. Med.* 21, 938–945.
- Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., and Mantovani, A. (2020). Neutrophil diversity and plasticity in tumour progression and therapy. *Nat. Rev. Cancer* 20, 485–503.
- Olson, O.C., and Joyce, J.A. (2015). Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. *Nat. Rev. Cancer* 15, 712–729.
- Papayannopoulos, V. (2018). Neutrophil extracellular traps in immunity and disease. *Nat. Rev. Immunol.* 18, 134–147.
- Ridker, P.M., MacFadyen, J.G., Thuren, T., Everett, B.M., Libby, P., and Glynn, R.J.; CANTOS Trial Group (2017). Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet* 390, 1833–1842.
- Ruffell, B., Affara, N.I., Cottone, L., Junankar, S., Johansson, M., DeNardo, D.G., Korets, L., Reinheckel, T., Sloane, B.F., Bogoyo, M., and Coussens, L.M. (2013). Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. *Genes Dev.* 27, 2086–2098.
- Xiao, Y., Cong, M., Li, J., He, D., Wu, Q., Tian, P., Wang, Y., Yang, S., Liang, C., Liang, Y., et al. (2021). Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. *Cancer Cell* 39, this issue, 423–437.
- Yang, L., Liu, Q., Zhang, X., Liu, X., Zhou, B., Chen, J., Huang, D., Li, J., Li, H., Chen, F., et al. (2020). DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. *Nature* 583, 133–138.